Pharmaceuticals UAE

UAE KRAS Inhibitors Market Analysis, 2024–2034

UAE KRAS Inhibitors Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UAE · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.5 Mn Estimated value
Estimate 2025 $6.1 Mn 0.6% of the global market
Projected 2034 $97.9 Mn 1,502.2% Adds $91.8 Mn over 9 forecast years
CAGR 2025–2034 36.1% Faster than 98% of 180 Pharmaceuticals markets here
Key players 5
  • UAE is 0.56% of the global market.
  • In Middle East, the largest is Saudi Arabia at $21.3 Mn.
  • Fastest growing: Saudi Arabia at 36.2% a year.
  • UAE ranks 2nd of 2 by size in Middle East.

Market size projection

UAE

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$91.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
KRAS Inhibitors Market market size by year, UAE
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.5 Mn — —
2025 (base) $6.1 Mn +$1.6 Mn —
2026 (forecast) $8.3 Mn +$2.2 Mn +36.1%
2027 (forecast) $11.3 Mn +$3.0 Mn +85.2%
2028 (forecast) $15.4 Mn +$4.1 Mn +152.1%
2029 (forecast) $21.0 Mn +$5.6 Mn +243.1%
2030 (forecast) $28.5 Mn +$7.6 Mn +367%
2031 (forecast) $38.8 Mn +$10.3 Mn +535.5%
2032 (forecast) $52.9 Mn +$14.0 Mn +765%
2033 (forecast) $72.0 Mn +$19.1 Mn +1,077.2%
2034 (forecast) $97.9 Mn +$26.0 Mn +1,502.2%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $1.09 Bn
  2. North America $489.3 Mn
  3. US $401.0 Mn
  4. APAC $210.2 Mn
  5. Europe $202.9 Mn
  6. China $93.6 Mn
  7. Canada $79.1 Mn
  8. Japan $72.2 Mn
  9. Latin America $51.3 Mn
  10. Middle East $38.8 Mn
  11. Germany $36.5 Mn
  12. France $32.1 Mn
  13. UK $30.6 Mn
  14. Brazil $30.4 Mn
  15. Italy $30.0 Mn
  16. Spain $22.1 Mn
  17. India $22.6 Mn
  18. Saudi Arabia $21.3 Mn
  19. Ecuador $19.0 Mn
  20. Mexico $16.0 Mn
  21. Africa $15.5 Mn
  22. Australia $13.6 Mn
  23. New Zealand $13.0 Mn
  24. Russia $10.7 Mn
  25. South Africa $8.2 Mn
  26. UAE (this report) $6.1 Mn
  27. Egypt $3.2 Mn
  28. Philippines $2.2 Mn
  29. Hong Kong $1.5 Mn
  30. Malaysia $1.5 Mn
  31. Singapore $1.3 Mn
  32. Thailand $1.3 Mn
  33. Kenya $0.7 Mn

The UAE KRAS Inhibitors Market Analysis Executive Summary

KRAS inhibitors target a common cancer-causing gene mutation that was long thought impossible to drug, mainly in lung and bowel cancers.

Key segments of the KRAS Inhibitors market include target (KRAS G12C, KRAS G12D and Pan-KRAS) and indication (Non-Small Cell Lung Cancer, Colorectal Cancer and Pancreatic Cancer).

UAE KRAS Inhibitors Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the KRAS Inhibitors market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the KRAS Inhibitors market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the KRAS Inhibitors market, especially in low- and middle-income countries.

Competitive Landscape for KRAS Inhibitors Market in UAE

The KRAS Inhibitors market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for KRAS Inhibitors Market in UAE

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for KRAS Inhibitors. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UAE.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in KRAS Inhibitors right now, from free public sources.

Latest research 440 papers since 2021 (worldwide)

  1. Random forest approach to predict genes correlated with adaptive responses to KRASG12C inhibitor. PloS one, 2026
  2. Simultaneous LC-MS/MS quantification of four KRAS inhibitors (RMC-6236, RMC-9805, RMC-7977, and MRTX1133) in human plasma: toward therapeutic drug monitoring in pancreatic ductal adenocarcinoma. Bioanalysis, 2026
  3. KRAS Inhibitor Resistance Confers a Targetable Vulnerability to Ferroptosis in Pancreatic Ductal Adenocarcinoma. Cancer research, 2026
  4. KRAS-mutated non-small cell lung cancer (NSCLC) in South India: Real-world genomic landscape, treatment patterns, and outcomes. Lung India : official organ of Indian Chest Society, 2026
  5. KRAS(G12D)-targeted therapy sensitivity depends on interferon signaling activation in pancreatic cancer. Cancer cell, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

KRAS Inhibitors in context

The UAE compared

  • Health spending per person: 2,402 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 9 countries we cover in Middle East.[1]
  • Doctors: 2.99 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 3rd highest of the 9 countries we cover in Middle East.[2]
  • People aged 65 and over: 1.8% of people (2025). World: 10.4% of people (2025). 8th highest of the 9 countries we cover in Middle East.[3]

Questions, answered with public data

How much research is published on KRAS Inhibitors?
PubMed lists 440 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about KRAS Inhibitors in UAE? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in UAE

See all
Same topic, other categories

Related on oncology

See the topic